Opioid UseNCT04868552
Naloxone Education in Total Joint Patients
A study testing Pre-hospital naloxone education in people with Opioid Use and Pain, Musculoskeletal, run by Carilion Clinic at 1 site in United States.
Trial summary
This study examines the efficacy of a brief pre-hospital naloxone education module added to the standard "Total Joint Class" curriculum on patient safety and experience. Participants will consist of 250 patient-and-support-person pairs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Opioid Use, Pain, Musculoskeletal, Surgery
- What is being tested?
- Pre-hospital naloxone education
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2021to Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients and "primary support person" pairs in which
- the patient is planning total or partial elective hip replacement at Carilion Roanoke Memorial Hospital OR
- the patient is planning total or partial elective knee replacement at Carilion Roanoke Memorial Hospital OR
- willingness to participate in study activities
Who cannot join
- Age < 18 years
- Pregnancy
- Poor cognitive function
- Poor English language skills
- Inmate
Trial locations and contacts
1 site in 1 country.
United States1 site
Institute for Orthopedics and Neurosciences
Roanoke, Virginia, 24014
About this study
Official title: The Effect of Universal Pre-hospital Naloxone Education on Patient and Family Safety, Attitudes and Experience in the Surgical Patient: a Prospective Randomized Trial
This study examines the efficacy of a brief pre-hospital naloxone education module added to the standard "Total Joint Class" curriculum on patient safety and experience. Participants will consist of 250 patient-and-support-person pairs. The primary outcome is "readiness to use" naloxone - a proxy for opioid overdose safety. Patient factors contributing to this primary outcome as well as the effect on patient attitude and experience will also be investigated.
Read the detailed description
Opioids are powerful pain medications which currently serve a necessary role in recovery after knee or hip replacement surgery. However, opioids also pose a danger to both the patient and to other members of the household in the event of accidental overdose because they can cause respiratory depression and death. To minimize the risk of opioid overdose, patients are educated in appropriate use and storage of their medication. They are also provided with a prescription for naloxone. Naloxone is an emergency-use, potentially life-saving antidote to opioid pain medication. It can be sprayed into the nostrils of the opioid overdose victim by a non-medically trained bystander while waiting for the ambulance to arrive, and can make the difference between life and death for a child or adult. However, only about 30% of patients choose to fill their naloxone prescription when they go home from hospital after joint replacement surgery at Carilion Roanoke Memorial Hospital. The first purpose of this study is to evaluate whether teaching patients about opioid overdose and naloxone treatment influences whether patients fill their naloxone prescription and whether they can appropriately administer naloxone in the event of an overdose in the home. Additionally, this study will look at what factors, other than pre-surgery education, influence whether a patient fills their naloxone prescription or not. The resources available for opioid overdose prevention in the community are limited, and this study will help guide the effective use of those resources.
The participants in this study will be patients who are planning hip or knee replacement surgery. They will enroll together with their primary support person. Two hundred and fifty patient and primary-support-person pairs will be enrolled prospectively over a 9-month period. All participant pairs will be randomized to receive either only the current three-hour pre-operative Joint Class (which is mandatory for all patients with their support person and includes education on opioids and pain management), or to receive, in addition, a new educational module. The new module will consist of a modified version of the REVIVE! Course, a course designed for people without prior medical training on the recognition of an opioid overdose and appropriate response including naloxone administration. Participants will be asked to complete an enrollment questionnaire prior to the educational intervention, a 2-week Recovery Journal (pain and medication diary) following surgery, and a follow-up questionnaire at the first post-operative visit, 2 weeks after surgery. Patients will also receive a short, 3-4 item questionnaire 6 months after surgery to collect data on the risk of long-term opioid use and the outcome of the naloxone in the home.
Demographic and clinical data that is collected will be used to describe the study population and determine factors that act as barriers to effective opioid overdose reversal with naloxone in the home. This study will also examine the influence of education on the experience of the patient within the healthcare system, attitudes of patients towards opioids and naloxone, and patient safety. Standardized assessments that will be used to address these study questions include the Opioid Overdose Knowledge Scale (OOKS), the Opioid Overdose Attitude Scale (OOAS), and the PROMIS Pain Medication Misuse, Pain Intensity, and Pain Interference short forms.
There are few studies that examine the influence of naloxone education for the layperson, so evidence in this field is limited. This study is unique in that it moves the conversation from the arena of chronic pain management and opioid addiction and focuses on the population of patients managing acute pain before and after surgical procedures. Outcomes of this research will help to direct prevention resources by answering very topical questions about the usefulness and effects of naloxone co-prescription with opioids for acute pain.
- Conditions
- Opioid Use, Pain, Musculoskeletal, Surgery, Overdose of Opiate
- Being tested
- Pre-hospital naloxone education
- Keywords
- naloxone, patient education, joint arthroplasty
- Medical subject headings
- Musculoskeletal Pain, Opiate Overdose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pre-hospital naloxone educationOther
a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
| Study group | Role | What they receive |
|---|---|---|
| Naloxone education | Experimental | These participants will receive a pre-hospital naloxone education module during their pre-operative joint class Receives: Other: Pre-hospital naloxone education |
| Standard Education | No intervention | These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting |
What is being measured
The primary outcome is the main question the study is designed to answer.
"Readiness to Use Naloxone" assessed by survey and Opioid Overdose Knowledge Scale administration
This measure is expressed as a binary yes/no for each patient-support person pair. It can be assessed with the survey tool used at the patient's follow up appointment. The patient/ support person pair must satisfy each of the three following conditions.
- patient reports naloxone is present in the home (or carried with the patient) (assessed by Y/N question)
- the support person reports knowledge of and immediate access to the naloxone (assessed by Y/N question)
- the support person demonstrates competency for naloxone administration by scoring a passing mark on the modified Opioid Overdose Knowledge Scale (OOKS) (Williams et al. 2013). For our purposes, this will be a score greater than or equal to 34/45.
If the three conditions are met, then the pair is assessed a "yes" score on "Readiness to Use Naloxone". If any condition is not met, then the pair is assessed a "no" score on "Readiness to Use Naloxone".
Measured: approximately 2 weeks (from surgery to first follow-up visit)
Secondary outcomes (17)
Correlation between indication for surgery (described by International Classification of Diseases 9/10 code) and "Readiness to Use Naloxone"
"Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
Indications for surgery are described by International Classification of Diseases 9/10, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include:
Musculoskeletal 16-Osteoarthritis of the Hip Musculoskeletal 17-Osteoarthritis of the Knee
Measured: 2 months (time from study enrollment to first post-op visit)
Correlation between procedure (Current Procedural Terminology code) and "Readiness to Use Naloxone"
"Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
The operations that patients undergo are described by Current Procedural Terminology codes, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include:
1005073- Arthroplasty, knee, condyle and plateau 27130 - Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft
Measured: 2 months (time from study enrollment to first post-op visit)
Correlation between patient comorbidities (described by International Classification of Diseases 9/10 code and "Readiness to Use Naloxone"
"Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
Comorbidities are other elements of a patient's health that are identified by their primary care physicians or other specialists. These comorbidities International Classification of Diseases 9/10, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include:
Musculoskeletal 16-Osteoarthritis of the Hip Musculoskeletal 17-Osteoarthritis of the Knee
Measured: 2 months (time from study enrollment to first post-op visit)
correlation between patient age and "Readiness to Use Naloxone"
age (exploratory analysis)
Measured: 2 months (time from study enrollment to first post-op visit)
correlation between patient sex and "Readiness to Use Naloxone"
sex (exploratory analysis)
Measured: 2 months (time from study enrollment to first post-op visit)
correlation between patient race and "Readiness to Use Naloxone"
race (exploratory analysis)
Measured: 2 months (time from study enrollment to first post-op visit)
correlation between patient ethnicity and "Readiness to Use Naloxone"
ethnicity (exploratory analysis)
Measured: 2 months (time from study enrollment to first post-op visit)
correlation between patient household income and "Readiness to Use Naloxone"
household income (exploratory analysis)
Measured: 2 months (time from study enrollment to first post-op visit)
Amount of opioid used at home
milligrams of morphine equivalents
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Interference 6a assessments
Each question usually has five response options ranging in value from one to five. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For the adult 6-item form, the lowest possible raw score is 6; the highest possible raw score is 30 (see all short form scoring tables in Appendix 1). All questions must be answered in order to produce a valid score using the scoring tables. If a participant has skipped a question, use the HealthMeasures Scoring Service (https://www.assessmentcenter.net/ac_scoringservice) to generate a final score. Locate the applicable score conversion table in Appendix 1 and use this table to translate the total raw score into a T-score for each participant. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean.
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Intensity 3a
Each question has five response options ranging in value from one to five. To find the total raw score for the short form, sum the values of the response to each question. The lowest possible raw score is 3; the highest possible raw score is 15.
For most Patient-Reported Outcomes Measurement Information System instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. The T-score is provided with an error term (Standard Error or SE). The Standard Error is a statistical measure of variance and represents the "margin of error" for the T-score.
Important: A higher Patient-Reported Outcomes Measurement Information System T-score represents more of the concept being measured.
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
High risk behavior as measured by the Patient Reported Outcome Measurement Information System Pain Medication Misuse assessment
Each question has five response options ranging in value from one to five. To find the total raw score for the short form, sum the values of the response to each question. For this instrument, the lowest possible raw score is 7; the highest possible raw score is 35. All questions must be answered in order to produce a valid score.
For most Patient-Reported Outcomes Measurement Information System instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. The T-score is provided with an error term (Standard Error or SE). The Standard Error is a statistical measure of variance and represents the "margin of error" for the T-score.
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
Patient and caregiver knowledge
Opioid Overdose Knowledge Scale: The Opioid Overdose Knowledge Scale items use a 'yes/no or don't know'; or 'true/false or don't know' response format.
Each correct answer scores one point. 'Don't know' and incorrectly marked responses (mistakes) are scored zero. Total score range: 0-45 points.
OPIOID OVERDOSE KNOWLEDGE SCALE (OOKS):
INSTRUCTIONS
Total Score (45 items):
One point if marked (33 Correct/True items): 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i, 2b, 2c, 2d, 2e, 2g, 2h, 3a, 3b, 3d, 3f, 3g, 3i, 3j, 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 12T, 14T One point if NOT marked (12 Incorrect/False items): 2a, 2f, 2i, 2j, 3c, 3e, 3h, 3k, 5d, 5e, 10F, 13F. You might chose to use the 'record into same variables' function of Statistical Package for the Social Sciences and inverse the values of these items.
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
Patient and caregiver attitude
Opioid Overdose Attitude Scale: SCORING The Opioid Overdose Attitude Scale is scored continuously using a 5-point Likert scale: completely disagree (1 point), disagree (2 points), unsure (3 points), agree (4 points) and completely agree (5 points).
Reverse negative items:
The following negative items need to be reversed before computing the total of scale points: 4, 6, 7, 9, 11, 15, 16, 17, 18, 23, 24, 25. You can use the 'record into same variables'
OPIOID OVERDOSE ATTITUDES SCALE (OOAS):
INSTRUCTIONS function of Statistical Package for the Social Sciences. Recode these items as: completely disagree (5 point), disagree (4 points), unsure (3 points), agree (2 points) and completely agree (1 points).
Totals Scores:
Once negative items have been reversed, add all items' points. The total scale points can range from 28 to 140 points.
Measured: 7 months (time from enrollment to 6 month follow-up phone call)
Prescription fill rate
patient reports naloxone is present in the home (or carried with the patient)
Measured: approximately 2 weeks (from surgery to first follow-up visit)
Naloxone accessibility
"yes/no" answer to the question: "Do you know where naloxone is stored in the home and have immediate access to it in an emergency?"
Measured: approximately 2 weeks (from surgery to first follow-up visit)
Rescuer competence measured by modified Opioid Overdose Knowledge Scale Score (see outcome 14 for scoring)
the support person demonstrates competency for naloxone administration by scoring a passing mark (34/45) on the modified Opioid Overdose Knowledge Scale
Measured: approximately 2 weeks (from surgery to first follow-up visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2021
- Study startSep 2021 (estimated)
- Primary completionJun 2022 (estimated)
- Study completionDec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Opioid UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- prospective randomized
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Carilion Clinic
- Sponsor type
- University, hospital or other
- Collaborators
- Virginia Polytechnic Institute and State University
- Responsible party
- Sponsor
- Investigators
- Cassandra Mierisch, MD, Principal investigator, Carilion Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04868552
- Sponsor's protocol ID
- IRB-19-474
- Status last verified
- Apr 2021
- First submitted
- 7 Oct 2019
- Last updated
- 3 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Universal Pre-hospital Naloxone Education on Patient and Family Safety, Attitudes and Experience in the Surgical Patient: a Prospective Randomized Trial
- ClinicalTrials.gov ID
- NCT04868552
- Acronym / sponsor ID
- IRB-19-474
- Conditions
- Opioid Use, Pain, Musculoskeletal, Surgery, Overdose of Opiate
- Keywords
- naloxone, patient education, joint arthroplasty
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Carilion ClinicUniversity, hospital or other
- Collaborators
- Virginia Polytechnic Institute and State University
- Study start
- Sep 2021 (estimated)
- Primary completion
- Jun 2022 (estimated)
- Study completion
- Dec 2022 (estimated)
- First posted
- 3 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examines the efficacy of a brief pre-hospital naloxone education module added to the standard "Total Joint Class" curriculum on patient safety and experience. Participants will consist of 250 patient-and-support-person pairs. The primary outcome is "readiness to use" naloxone - a proxy for opioid overdose safety. Patient factors contributing to this primary outcome as well as the effect on patient attitude and experience will also be investigated.
Detailed description
Opioids are powerful pain medications which currently serve a necessary role in recovery after knee or hip replacement surgery. However, opioids also pose a danger to both the patient and to other members of the household in the event of accidental overdose because they can cause respiratory depression and death. To minimize the risk of opioid overdose, patients are educated in appropriate use and storage of their medication. They are also provided with a prescription for naloxone. Naloxone is an emergency-use, potentially life-saving antidote to opioid pain medication. It can be sprayed into the nostrils of the opioid overdose victim by a non-medically trained bystander while waiting for the ambulance to arrive, and can make the difference between life and death for a child or adult. However, only about 30% of patients choose to fill their naloxone prescription when they go home from hospital after joint replacement surgery at Carilion Roanoke Memorial Hospital. The first purpose of this study is to evaluate whether teaching patients about opioid overdose and naloxone treatment influences whether patients fill their naloxone prescription and whether they can appropriately administer naloxone in the event of an overdose in the home. Additionally, this study will look at what factors, other than pre-surgery education, influence whether a patient fills their naloxone prescription or not. The resources available for opioid overdose prevention in the community are limited, and this study will help guide the effective use of those resources.
The participants in this study will be patients who are planning hip or knee replacement surgery. They will enroll together with their primary support person. Two hundred and fifty patient and primary-support-person pairs will be enrolled prospectively over a 9-month period. All participant pairs will be randomized to receive either only the current three-hour pre-operative Joint Class (which is mandatory for all patients with their support person and includes education on opioids and pain management), or to receive, in addition, a new educational module. The new module will consist of a modified version of the REVIVE! Course, a course designed for people without prior medical training on the recognition of an opioid overdose and appropriate response including naloxone administration. Participants will be asked to complete an enrollment questionnaire prior to the educational intervention, a 2-week Recovery Journal (pain and medication diary) following surgery, and a follow-up questionnaire at the first post-operative visit, 2 weeks after surgery. Patients will also receive a short, 3-4 item questionnaire 6 months after surgery to collect data on the risk of long-term opioid use and the outcome of the naloxone in the home.
Demographic and clinical data that is collected will be used to describe the study population and determine factors that act as barriers to effective opioid overdose reversal with naloxone in the home. This study will also examine the influence of education on the experience of the patient within the healthcare system, attitudes of patients towards opioids and naloxone, and patient safety. Standardized assessments that will be used to address these study questions include the Opioid Overdose Knowledge Scale (OOKS), the Opioid Overdose Attitude Scale (OOAS), and the PROMIS Pain Medication Misuse, Pain Intensity, and Pain Interference short forms.
There are few studies that examine the influence of naloxone education for the layperson, so evidence in this field is limited. This study is unique in that it moves the conversation from the arena of chronic pain management and opioid addiction and focuses on the population of patients managing acute pain before and after surgical procedures. Outcomes of this research will help to direct prevention resources by answering very topical questions about the usefulness and effects of naloxone co-prescription with opioids for acute pain.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- prospective randomized
| Arm | Type | Receives |
|---|---|---|
| Naloxone education | Experimental | Other: Pre-hospital naloxone educationThese participants will receive a pre-hospital naloxone education module during their pre-operative joint class |
| Standard Education | No intervention | –These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients and "primary support person" pairs in which
- the patient is planning total or partial elective hip replacement at Carilion Roanoke Memorial Hospital OR
- the patient is planning total or partial elective knee replacement at Carilion Roanoke Memorial Hospital OR
- willingness to participate in study activities
Key exclusion criteria (5 listed)
- Age < 18 years
- Pregnancy
- Poor cognitive function
- Poor English language skills
- Inmate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pre-hospital naloxone educationa 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone | Other | Naloxone education |
Primary outcome
"Readiness to Use Naloxone" assessed by survey and Opioid Overdose Knowledge Scale administration
Time frame: approximately 2 weeks (from surgery to first follow-up visit)
This measure is expressed as a binary yes/no for each patient-support person pair. It can be assessed with the survey tool used at the patient's follow up appointment. The patient/ support person pair must satisfy each of the three following conditions. 1. patient reports naloxone is present in the home (or carried with the patient) (assessed by Y/N question) 2. the support person reports knowledge of and immediate access to the naloxone (assessed by Y/N question) 3. the support person demonstrates competency for naloxone administration by scoring a passing mark on the modified Opioid Overdose Knowledge Scale (OOKS) (Williams et al. 2013). For our purposes, this will be a score greater than or equal to 34/45. If the three conditions are met, then the pair is assessed a "yes" score on "Readiness to Use Naloxone". If any condition is not met, then the pair is assessed a "no" score on "Readiness to Use Naloxone".
17 secondary outcomes
Correlation between indication for surgery (described by International Classification of Diseases 9/10 code) and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
Correlation between procedure (Current Procedural Terminology code) and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
Correlation between patient comorbidities (described by International Classification of Diseases 9/10 code and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
correlation between patient age and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
correlation between patient sex and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
correlation between patient race and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
correlation between patient ethnicity and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
correlation between patient household income and "Readiness to Use Naloxone"
Time frame: 2 months (time from study enrollment to first post-op visit)
Amount of opioid used at home
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Interference 6a assessments
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Intensity 3a
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
High risk behavior as measured by the Patient Reported Outcome Measurement Information System Pain Medication Misuse assessment
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
Patient and caregiver knowledge
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
Patient and caregiver attitude
Time frame: 7 months (time from enrollment to 6 month follow-up phone call)
Prescription fill rate
Time frame: approximately 2 weeks (from surgery to first follow-up visit)
Naloxone accessibility
Time frame: approximately 2 weeks (from surgery to first follow-up visit)
Rescuer competence measured by modified Opioid Overdose Knowledge Scale Score (see outcome 14 for scoring)
Time frame: approximately 2 weeks (from surgery to first follow-up visit)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2021.
- Individual participant dataSharing planned: No
Related trials for Opioid Use
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cassandra Mierisch, MD principal investigator
Carilion Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pre-hospital naloxone education in people with Opioid Use and Pain, Musculoskeletal, run by Carilion Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Cassandra Mierisch, MD (540-510-6200, crmierisch@carilionclinic.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
"Readiness to Use Naloxone" assessed by survey and Opioid Overdose Knowledge Scale administration (time frame: approximately 2 weeks (from surgery to first follow-up visit)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2021.